Shire plc, of Dublin, acknowledged two petitions filed with the Patent and Trademark Office on April 2 by Hayman Capital Management regarding Lialda (mesalamine) and Gattex (teduglutide [rDNA origin]) and said it will pursue all legal options and vigorously defend its patents, which are listed in the FDA Orange Book.